Notification That Annual Report Will Be Submitted Late (nt 10-k)
March 16 2020 - 5:17PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
|
SEC
FILE NUMBER
000-26372
|
FORM
12b –25
NOTIFICATION
OF LATE FILING
|
CUSIP
NUMBER
00547W208
|
Check
One:
☒
Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CSR
For
Period Ended: December 31, 2019
☐
Transition
Report on Form 10-K
☐
Transition
Report on Form 20-F
☐
Transition
Report on Form 11-K
☐
Transition
Report on Form 10-Q
☐
Transition
Report on Form N-SAR
For
the Transition Period Ended: __________________________
If
the notification relates to a portion of the filing check above, identify the Item(s) to which the notification relates:
PART
I -- REGISTRANT INFORMATION
Adamis
Pharmaceuticals Corporation
|
Full Name of Registrant
|
|
Former Name if
Applicable
|
11682
El Camino Real, Suite 300
|
Address of Principal
Executive Office (Street and Number)
|
San
Diego, CA 92130
|
City, State and
Zip Code
|
PART
II -- RULES 12b - 25(b) and (c)
|
If
the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule
12b - 25(b), the following should be completed. (Check box if appropriate.)
|
|
(a)
|
The
reasons described in reasonable detail in Part III of this form could not be eliminated
without unreasonable effort expense;
|
|
☒
|
(b)
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or a portion thereof will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or subject distribution report on Form 10-D, or a portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
|
|
☐
|
(c)
The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
State
below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR, N-CSR, or the transition report or portion thereof
could not be filed within the prescribed time period. (Attach extra sheets if needed.)
Adamis
Pharmaceuticals Corporation (the “Registrant” or the “Company”) is filing this Notification of Late
Filing on Form 12b-25 with respect to its Annual Report on Form 10-K for the fiscal year ended December 31, 2019 (the
“Form 10-K”) because it needs additional time to prepare and review certain information and complete its review
of its financial statements and other disclosures in the Form 10-K, including without limitation regarding assessing
the impact of the recent coronavirus outbreak and declared national emergency, and related state actions, on the financial
statements and other disclosures in the Form 10-K in light of, among other things, recent statements from the Securities and
Exchange Commission and the Public Company Accounting Oversight Board, and the annual assessment of the impairment of its
goodwill and indefinite-lived intangible assets, which
could not be completed by the date required without incurring unreasonable effort and expense. The Company anticipates
that it will file its Form 10-K as soon as reasonably possible and within the 15-day grace period provided by Rule 12b-25 of
the Securities Exchange Act of 1934, as amended.
PART
IV – OTHER INFORMATION
|
|
(1)
|
Name
and telephone number of person to contact in regard to this notification.
|
|
Robert O. Hopkins
|
(858) 997-2400
|
|
(Name)
|
(Area
Code and Telephone Number)
|
|
(2)
|
Have
all other periodic reports required under section 13 or 15(d) of the Securities Exchange
Act of 1934 or section 30 of the Investment Company Act of 1940 during the preceding
12 months or for such shorter period that the registrant was required to file such report(s)
been filed? If the answer is no, identify report(s).
|
☒
Yes ☐ No
|
(3)
|
Is
it anticipated that any significant change in results of operations from the corresponding
period for the last fiscal year will be reflected by the earnings statements to be included
in the subject report or portion thereof?
|
☒
Yes ☐ No
For the reasons stated above in Part III, the Company cannot
reasonably estimate at this time the anticipated change to its results of operations, but it expect the Company’s revenue
to increase, and its net loss to decrease, compared to the prior year ended December 31, 2018.
Adamis Pharmaceuticals Corporation
|
(Name
of Registrant as specified in its charter)
|
has
caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.
Date: March
16, 2020
|
By:
|
/s/ ROBERT O. HOPKINS
|
|
|
Robert O. Hopkins
|
|
|
Chief Financial Officer
|
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Apr 2023 to Apr 2024